iTeos Therapeutics, Inc. (ITOS)

11.66 +0.17 (+1.48%) At close: 04:00PM EDT

iTeos Therapeutics, Inc.

321 Arsenal Street
Suite 301 Building 312
Watertown, MA 02472
United States
339 217 0161
https://www.iteostherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 157

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Michel Detheux Ph.D.	President, CEO & Director	1.04M	N/A	1967
Mr. Matthew Gall	Chief Financial Officer	648k	N/A	1977
Mr. Matthew A. Call M.B.A.	Chief Operating Officer	706.21k	N/A	1973
Dr. Yvonne McGrath Ph.D.	Chief Scientific Officer	N/A	N/A	1974
Ms. Adi Osovsky	Executive Vice President of Legal	N/A	N/A	N/A
Mr. Philippe Brantegem	Executive Vice President of Human Resources	N/A	N/A	N/A
Dr. Joyson Joseph Karakunnel FACP, M.D., M.Sc.	Interim Chief Medical Officer	N/A	N/A	1971

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Corporate governance

iTeos Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 9; Board: 8; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.